EyePoint Pharmaceuticals Files 8-K

Ticker: EYPT · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1314102

Eyepoint Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyEyepoint Pharmaceuticals, Inc. (EYPT)
Form Type8-K
Filed DateFeb 5, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: corporate-disclosure, sec-filing

Related Tickers: EYPT

TL;DR

EYPT filed a routine 8-K, no major news yet.

AI Summary

EyePoint Pharmaceuticals, Inc. filed an 8-K on February 5, 2025, reporting its status as a Delaware corporation with its principal executive offices in Watertown, Massachusetts. The company's common stock trades on The Nasdaq Global Market under the ticker symbol EYPT. The filing does not disclose any specific material events or financial transactions.

Why It Matters

This 8-K filing serves as a standard corporate disclosure, confirming EyePoint Pharmaceuticals' reporting status and stock exchange listing without detailing any new material events.

Risk Assessment

Risk Level: low — This filing is a standard corporate disclosure and does not contain information that inherently increases or decreases risk.

Key Players & Entities

  • EyePoint Pharmaceuticals, Inc. (company) — Registrant
  • February 05, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • Watertown, Massachusetts (location) — Principal Executive Offices
  • EYPT (ticker) — Trading Symbol for Common Stock
  • The Nasdaq Global Market (exchange) — Exchange where Common Stock is registered

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report current information as required by the Securities Exchange Act of 1934, specifically noting the date of the earliest event reported and the company's basic corporate information.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on February 05, 2025.

Where are EyePoint Pharmaceuticals, Inc.'s principal executive offices located?

EyePoint Pharmaceuticals, Inc.'s principal executive offices are located at 480 Pleasant Street, Watertown, Massachusetts, 02472.

On which exchange is EyePoint Pharmaceuticals, Inc.'s common stock traded?

EyePoint Pharmaceuticals, Inc.'s common stock is traded on The Nasdaq Global Market.

Does this filing indicate any specific material events or financial changes for EyePoint Pharmaceuticals?

No, this filing is a standard current report and does not disclose any specific material events or financial transactions beyond confirming the company's reporting status and listing information.

Filing Stats: 477 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-02-05 07:05:19

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Ind

Filing Documents

01 Other Events

Item 8.01 Other Events. On February 5, 2025, EyePoint Pharmaceuticals, Inc. (the "Company") issued a press release announcing positive topline results for its ongoing Phase 2 VERONA clinical trial evaluating DURAVYU for diabetic macular edema. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. Additionally, on February 5, 2025, the Company posted an updated investor presentation on its website at www.eyepointpharma.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of EyePoint Pharmaceuticals, Inc., dated February 5, 2025 99.2 Investor Presentation of EyePoint Pharmaceuticals, Inc. dated February 5, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT PHARMACEUTICALS, INC. Date: February 5, 2025 By: /s/ George O. Elston George O. Elston Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.